oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma
Department of Urology, Örebro Medical Centre, Örebro, Sweden.
Department of Pathology, Örebro Medical Centre, Örebro, Sweden.ORCID iD: 0000-0001-6881-237X
2000 (English)In: Cancer, ISSN 0008-543X, E-ISSN 1097-0142, Vol. 89, no 3, 619-629 p.Article in journal (Refereed) Published
Abstract [en]

Background: The aim of this study was to elucidate the associations among immunostaining for p53, p21, and mdm2; their respective expression within each tumor; and the value of these variables for predicting treatment outcome after cystectomy for patients with locally advanced bladder carcinoma.

Methods: The hospital records from all 173 patients treated with cystectomy for locally advanced urothelial bladder carcinoma between 1967 and 1992 were retrospectively reviewed. Three consecutive sections from biopsies taken before any treatment were stained using the standard immunohistochemical technique for p53, p21, and mdm2, respectively. The cutoff limit was 20% or more for positive p53 expression and 10% or more for positive p21 and mdm2 expression.

Results: Positive immunostaining was observed for p53 in 98 tumors (57%), for p21 in 89 tumors (51%), and for mdm2 in only 16 tumors (9%). The only association found between immunostaining for the three antibodies was that most mdm2-positive tumors had positive p21 expression. Tumor mapping of regional immunostaining showed no association between immunostaining for p53 and p21. In a proportional hazards analysis, no association was found between the results of immunostaining for the three antibodies and treatment outcome.

Conclusions: Positive or negative expression of p53, p21, or mdm2, or combinations of these, was not associated with cancer specific mortality after cystectomy for bladder carcinoma. There was no association between immunostaining for p21 and p53, whereas positive immunostaining for mdm2 was observed in a minority of the tumors. These results indicate that, in addition to p21, p53, and mdm2, there are other oncoproteins and tumor suppressor proteins along the p53 pathway that are involved in tumor development and progression.

Place, publisher, year, edition, pages
New York, USA: John Wiley & Sons, 2000. Vol. 89, no 3, 619-629 p.
Keyword [en]
p53, p21, mdm2, bladder carcinoma, cystectomy, tumor suppressor function, prognosis
National Category
Cancer and Oncology Clinical Laboratory Medicine Urology and Nephrology
Identifiers
URN: urn:nbn:se:oru:diva-49519DOI: 10.1002/1097-0142(20000801)89:3<619::AID-CNCR18>3.0.CO;2-4ISI: 000088527200018PubMedID: 10931462Scopus ID: 2-s2.0-0034255307OAI: oai:DiVA.org:oru-49519DiVA: diva2:914876
Available from: 2016-03-27 Created: 2016-03-25 Last updated: 2017-10-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Karlsson, Mats G.
In the same journal
Cancer
Cancer and OncologyClinical Laboratory MedicineUrology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 232 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf